RA Capital Management is a Boston-based investment advisor founded in 2004, specializing in the life sciences and healthcare sectors. The firm focuses on early-stage companies developing innovative technologies, products, and services in drug development, medical devices, diagnostics, and research tools. With a team of professionals trained in biology, chemistry, and medicine, RA Capital Management leverages its extensive industry and business development experience to identify and invest in promising healthcare ventures. As a Registered Investment Adviser, the firm employs a strategic approach that includes both venture capital investments and a hedge fund strategy, targeting opportunities primarily in the United States and Europe.
The National Institutes of Health (NIH) is a leading biomedical research facility in the United States, operating under the Department of Health and Human Services. Established in 1887 and based in Bethesda, Maryland, NIH is the primary agency responsible for biomedical and health-related research in the country. It comprises 27 separate institutes and centers, each focusing on different disciplines within biomedical science. NIH conducts its own scientific research through the Intramural Research Program and provides significant funding for research at external institutions via the Extramural Research Program. With a workforce that includes 1,200 principal investigators and over 4,000 postdoctoral fellows, NIH has been instrumental in major medical breakthroughs, such as the development of vaccines for hepatitis and human papillomavirus, as well as the discovery of treatments for various health conditions. As the world's largest source of medical research funding, NIH continues to advance scientific knowledge and contribute to public health improvements.
OrbiMed is a healthcare-focused investment firm based in New York City, established in 1989. The firm specializes in providing a range of financing solutions, including bridge loans, senior debt, and structured debt capital for both commercial-stage public and private healthcare companies. OrbiMed invests across various sectors within the healthcare industry, such as pharmaceuticals, life sciences, digital health, medical devices, biopharmaceuticals, diagnostics, healthcare technology, and biotechnology. With approximately $5 billion in assets under management, OrbiMed aims to support a spectrum of healthcare companies, from early-stage ventures to established multinational corporations.
Perceptive Advisors LLC is an investment management firm established in 1999, with headquarters in New York City and an additional office in Boston. The firm specializes in supporting the life sciences sector, investing primarily in biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. Perceptive Advisors engages in venture capital and incubation, making equity investments ranging from $10 million to $200 million in both private and public companies. It manages client-focused equity portfolios and employs a long/short equity strategy as part of its hedging techniques. Additionally, the firm conducts in-house research and utilizes technical analysis to inform its investment decisions. Perceptive Advisors also provides customized debt financing solutions through its Perceptive Credit Opportunities Fund, catering to the evolving needs of healthcare companies.
SOSV is a global venture capital firm based in Princeton, New Jersey, founded in 1995. It specializes in early-stage investments, focusing on deep technology innovations that address human and planetary health. The firm operates startup development programs, notably HAX and IndieBio, which provide resources, facilities, and lab equipment to accelerate the growth of promising startups. SOSV supports companies from their inception through various funding stages, including seed and series A rounds, while offering ongoing assistance to help them scale and attract additional investors. By concentrating on revolutionary technologies and cross-border markets, particularly in Asia, SOSV aims to foster significant advancements that benefit humanity and the environment.
Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, founded in 2006. With additional offices in Beijing, Suzhou, Hong Kong, and Singapore, the firm focuses on early to growth-stage investments across various sectors, including healthcare, information technology, consumer goods, mobile internet, artificial intelligence, and clean technology. Qiming Venture Partners has a strong track record, having invested in over 530 innovative companies, with more than 200 achieving successful exits through public offerings or mergers and acquisitions. The firm is recognized for its deep technical expertise and hands-on operational support, making it a preferred partner for CEOs and startups seeking to scale their operations. Its partners are often sought after as board members, reflecting their status as respected business leaders and thought leaders in the venture capital landscape.
Samsara BioCapital LLC is a principal investment firm established in 2016 and located in Palo Alto, California. The company specializes in providing investment advisory services aimed at supporting biotechnology firms and entrepreneurs in transforming their ideas into successful ventures. It focuses on sectors such as healthcare, life sciences, oncology, and digital health, emphasizing innovation in the development of new therapies. Samsara BioCapital actively seeks to partner with ambitious and visionary companies, fostering collaboration to advance significant advancements in biotechnology.
Biotechnology Value Fund is a San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments. Since its inception in 1993, BVF has strived to build concentrated, long-term investments in small-cap biotechnology companies while performing rigorous diligence and on-going monitoring of its investments. BVF is committed to working with its portfolio companies as partners in their successes.
Novo Holdings is a Danish holding and investment firm based in Copenhagen, wholly owned by the Novo Nordisk Foundation. Established in 1999, it manages the Foundation's financial assets and aims to ensure sufficient dividends to support its grant obligations for medical and scientific research. Novo Holdings primarily invests in the life science sector, maintaining a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private investments. It holds a significant ownership stake in Novo Nordisk A/S and Novozymes A/S, ensuring a material influence over these companies. The firm actively participates in their governance and is committed to supporting early-stage applied research in life sciences through initiatives like Novo Seeds. By investing in both early and later-stage life science companies, Novo Holdings seeks to balance financial risk while aiming for high returns, all within a framework of shared values and management principles across the Novo Group.
ARCH Venture Partners, founded in 1986 and based in Chicago, Illinois, is a venture capital firm that specializes in investing in early-stage technology companies, particularly in the life sciences sector. The firm focuses on innovations that emerge from academic research institutions and national laboratories, making it a recognized leader in the commercialization of such technologies. ARCH invests conservatively in seed rounds to mitigate risk and subsequently leads or co-leads further financing rounds, aiming for a seat on the Board of Directors. Its investment strategy encompasses a wide range of sectors, including biotechnology, pharmaceuticals, advanced materials, and clean technology, among others. ARCH primarily invests in the United States while also targeting opportunities in countries like Canada, Ireland, South Korea, China, and Japan. The firm has raised over $3 billion across ten venture funds and has supported more than 150 companies in their early capital rounds.
Janus Henderson Investors is a global asset management firm headquartered in London, United Kingdom, with a history dating back to 1934. The company specializes in delivering investment performance and services to a diverse clientele, including institutional, retail, and high-net-worth clients. It connects these clients with investment professionals who have expertise across a wide range of asset classes, such as equities, fixed income, real estate, and alternative investments. Janus Henderson Investors aims to provide tailored investment solutions that meet the unique needs of its clients while fostering long-term financial growth.
Invus Financial Advisors, LLC is an employee-owned investment firm based in New York, founded in 2006. The firm specializes in private equity investments and manages pooled investment vehicles, including hedge funds and funds of funds. Invus focuses on making direct and indirect investments in special situations, venture capital, and growth equity stages, with an emphasis on smaller companies and opportunistic co-investments. The firm adopts a flexible approach, recognizing the uniqueness of each company and the complexities of business transformation. Invus maintains a long-term commitment to its investments, aligning its incentives with those of its partners. With a history of empowering owner-managers since 1985 and a strong backing from a group of European families, Invus Financial Advisors manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong.
Pfizer is a global biopharmaceutical company dedicated to advancing medical care and improving patient outcomes through the development and provision of safe, effective, and affordable medicines. The company offers a diverse portfolio of products that support wellness, prevention, and treatment across a wide range of therapeutic areas. Pfizer is notable for its industry-leading pipeline of innovative treatments aimed at addressing significant health challenges, including diseases such as Alzheimer's and cancer. The company's commitment to public health underpins its efforts to ensure that all individuals have access to necessary healthcare services and medications. Through its continuous focus on research and development, Pfizer seeks to enhance its offerings and contribute to the advancement of global health.
Vivo Capital is a global investment firm established in 1996 and headquartered in Palo Alto, California, with additional offices in Asia. With approximately $5.8 billion in assets under management, Vivo has invested in over 290 public and private companies, primarily within the healthcare sector. The firm employs a team of 50 professionals who possess diverse expertise, including physicians, scientists, entrepreneurs, and industry executives. Vivo Capital operates as a multi-fund investment platform, engaging in strategies that encompass growth equity, private equity, venture capital, and public equity. Its investment focus spans various healthcare subsectors, including biopharmaceuticals, specialty pharmaceuticals, medical devices, and healthcare services, with an emphasis on significant healthcare markets in the United States and East Asia.
Alexandria Venture Investments, LLC is a venture capital firm established in 1996 and located in Pasadena, California. As a subsidiary of Alexandria Real Estate Equities, the firm specializes in seed, early-stage, and growth capital investments primarily within the healthcare sector. Its focus areas include biopharma, diagnostics, life sciences, research tools, agrifood technology, and technology. By leveraging its extensive industry expertise and a robust network of relationships with leading investors and scientific advisors, Alexandria Venture Investments aims to support innovative companies that are developing breakthrough technologies and therapies to enhance human health.
The European Innovation Council (EIC), established in 2020 and headquartered in Brussels, Belgium, is dedicated to supporting high-potential innovators, entrepreneurs, small enterprises, and researchers. Its primary focus is on fostering early-stage startups that demonstrate significant environmental, social, and governance (ESG) impacts. The EIC collaborates with private investors to co-invest in ventures, particularly within the deep technology sector, aiming to drive innovation and sustainable development across Europe. By providing financial backing and resources, the EIC seeks to enhance the growth potential of promising startups and contribute to a more innovative and competitive European economy.
Innovate U.K. is a NPO that offers funding services to support science and technology innovations. The organization offers services and information on births, deaths, marriages, business, self-employed, childcare, parenting, citizenship, law, disabled persons, transportation, education, environment, housing, money, tax, travel, immigration, and jobs. Innovate U.K. is based in Swindon.
Deep Track Capital is a private equity investment firm established in 2020 and based in Greenwich, Connecticut. It specializes in the life sciences and biotechnology sectors, focusing on forming partnerships with management teams of innovative public and pre-IPO biotechnology companies. The firm aims to leverage its expertise and extensive network to provide value beyond capital, actively participating in transactions and often leading investment rounds while collaborating with other qualified investors. As a Registered Investment Adviser, Deep Track Capital is dedicated to fostering growth and innovation within the life sciences industry.
New Enterprise Associates, Inc. is a private equity and venture capital firm founded in 1977 and headquartered in Menlo Park, California, with additional offices in India and China. The firm specializes in investing across various stages of business development, from seed funding to public offerings, with a strong emphasis on the technology and healthcare sectors. Its investment strategy encompasses a wide range of industries, including information technology, consumer internet, financial technology, software, healthcare services, life sciences, biopharmaceuticals, and energy technology. New Enterprise Associates actively engages with entrepreneurs to support the growth of their companies, making investments between $0.05 million and $20 million. The firm has a global investment focus, particularly in regions such as Asia, Brazil, and the United States.
Surveyor Capital is a fundamental equities business. Surveyor’s sector-aligned investment teams aim to generate alpha through a deep understanding of each company’s strategy, management teams, drivers of performance, and cyclical and secular industry trends over the medium and long term.
The National Science Foundation (NSF) is an independent federal agency established in 1950 and based in Alexandria, Virginia. It is dedicated to supporting research and education in science and engineering across a wide range of disciplines. The NSF provides significant non-dilutive funding, up to $1.5 million, to startups and small businesses through its America's Seed Fund initiative, which is part of the Small Business Innovation Research (SBIR) program mandated by Congress. With an operating budget of approximately $7.8 billion, the NSF is committed to advancing fundamental research and education, thus fostering innovation and technological development in the United States.
Adage Capital Management is a Boston-based $8.9B Money Management firm focused on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation. Adage and its predecessor, the Select Equity Group at the Harvard Management Company, has outperformed the S&P index in each of the last 15 years by an average of 3.5%. The fund is run by Phill Gross, who prior to founding Adage, was a Healthcare and Retail analyst, equity research director and partner at the Harvard Management Company for 18 years..
Polaris Partners is a multibillion-dollar investment firm founded in 1996 and headquartered in Boston, Massachusetts, with an additional office in San Francisco. The firm specializes in investing in healthcare and biotechnology companies, focusing on various aspects of the sector. Its healthcare portfolio includes companies that develop innovative care delivery models, such as digital health solutions, consumer-centric services, patient-provider interactions, as well as data science and analytics. In the biotechnology realm, Polaris targets life sciences firms engaged in research and development of therapeutics, genomic technologies, and molecular platforms. With over 20 years of experience, Polaris Partners collaborates with repeat entrepreneurs and innovators, supporting ventures from their inception through to profitable growth.
Versant Ventures is a healthcare investment firm founded in 1999 and based in San Francisco, California. It focuses on supporting exceptional entrepreneurs in building innovative companies across various sectors within healthcare, including biotechnology, life sciences, pharmaceuticals, and oncology. With $2.3 billion under management, the firm invests at all stages of company development, emphasizing the discovery and development of novel therapeutics. Versant’s team possesses extensive investment, operational, and scientific expertise, allowing for a hands-on approach to company building. Since its inception, more than 65 companies associated with Versant have successfully achieved acquisitions or initial public offerings, reflecting the firm’s commitment to fostering growth in the healthcare industry.
RTW Investments, LP is an employee-owned hedge fund manager based in New York, with additional offices in London and Shanghai. Established in 2009, the firm specializes in investments within the healthcare sector, focusing on life sciences, big data, and digital health. RTW Investments engages in a comprehensive investment strategy that spans the entire lifecycle of healthcare companies, including company creation, early-stage venture capital, alternative financing, and public company investments. The firm conducts thorough in-house fundamental research to inform its investment decisions, managing both pooled investment vehicles and separate client-focused equity and fixed income portfolios.
EcoR1 Capital, LLC is an employee-owned investment advisory firm based in San Francisco, California, founded in 2012. Specializing in the biotechnology sector, EcoR1 Capital focuses on identifying and evaluating innovative therapeutic solutions that can significantly enhance patient outcomes. The firm employs a long/short investment strategy primarily within the public equity markets of the United States, while also managing separate client-focused equity and fixed income portfolios. By investing in biotech companies that offer promising new treatments for untreated diseases, EcoR1 Capital aims to advance medical research and build upon the innovative contributions of its predecessors in the healthcare and life sciences fields.
Deerfield Management is a New York-based healthcare company founded in 1994 that operates across investment, information, and philanthropy. As a registered investment adviser, it focuses on providing a robust healthcare ecosystem through various investment strategies. The firm engages in both private and public investments, targeting companies within the life sciences, medical device, diagnostic, digital health, and health services sectors. Deerfield's commitment extends beyond financial support, as it also emphasizes the importance of information and philanthropy in enhancing healthcare outcomes.
GV Investment Managers is a private equity firm founded in 2000 and based in Stamford, Connecticut. The firm specializes in impact investing, private equity, and portfolio management services. It focuses on sectors such as life sciences, consumer products, enterprise solutions, cryptocurrency, climate technology, and frontier innovations. With Alphabet as its sole limited partner, GV Investment Managers primarily targets investments in North America and Europe. The firm collaborates with operating partners who assist startups in areas such as design, diversity and inclusion, talent acquisition, and engineering, while also facilitating connections with Google for technological support and expertise.
Rock Springs Capital is an investment company based in Baltimore, Maryland, established in 2013. It specializes in the healthcare and biotechnology sectors, offering advisory services that focus on managing security portfolios and providing portfolio management solutions for businesses and institutional clients. The firm aims to assist clients in optimizing their investment strategies and achieving their financial objectives through its comprehensive management services.
The Bill & Melinda Gates Foundation is an independent non-profit organization based in Seattle, Washington, established in 2000. It is dedicated to reducing global inequities by focusing on improving health, alleviating extreme poverty, and supporting educational initiatives. The foundation also engages in community giving within the Pacific Northwest, promoting strategies and programs that assist low-income families. With regional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom, the foundation is governed by its co-founders, Bill and Melinda Gates, along with trustee Warren Buffett. Its mission encompasses a wide range of global challenges, aiming to create lasting change through targeted grant-making and programmatic efforts.
Lilly Asia Ventures, established in 2008 and based in Shanghai, China, serves as the corporate venture capital arm of Eli Lilly and Company. The firm focuses on making investments in promising life science companies that exhibit strong management teams and innovative technologies or business models. While its primary investment strategy targets opportunities in China, Lilly Asia Ventures is also open to exploring prospects in other regions of East and South Asia. The firm invests across various stages, including seed, early, and later stages, with particular interest in sectors such as healthcare, life sciences, oncology, manufacturing, and technology-based industries. Through its investments, Lilly Asia Ventures aims to foster the development of innovative solutions that contribute to improved health and quality of life.
Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.
F-Prime Capital is a venture capital firm established in 1969 and headquartered in Cambridge, Massachusetts, with additional offices in San Francisco and London. It is part of the Fidelity Investments family, which has a long history of supporting entrepreneurs. F-Prime Capital focuses its investments on companies in North America and Europe, specializing in sectors such as healthcare, life sciences, therapeutics, fashion, medtech, health information technology and services, and technology. The firm emphasizes a hands-on approach, leveraging its deep industry expertise and extensive relationships to assist entrepreneurs in building significant companies. F-Prime Capital operates without the pressures of external fundraising, allowing it to concentrate on identifying and nurturing promising ventures.
Sofinnova Partners is a venture capital firm founded in 1972 and headquartered in Paris, France. The firm specializes in investing in the life sciences sector, focusing on biopharmaceuticals, biotechnology, medical devices, and industrial biotechnology. With over €2 billion in assets dedicated to life science investments, Sofinnova Partners partners with entrepreneurs at various stages, from seed to later-stage companies, including start-ups and corporate spin-offs. The firm actively seeks to take a lead role in financing, often becoming the first institutional investor in Series A rounds. It maintains an engaged presence in its portfolio companies by sitting on their boards and supporting them through to exit, thereby fostering transformative innovations that have the potential to make a significant positive impact on society.
IndieBio, founded in 2014 and based in San Francisco, is the world’s first accelerator dedicated to startups that leverage biology to address significant global challenges. As part of SOSV, a global venture capital firm, IndieBio focuses on nurturing seed-stage and early-stage companies across various sectors, including healthcare, life sciences, biotechnology, and consumer products. The accelerator provides funding and support to innovative ventures aiming to create impactful solutions in areas such as pharmaceuticals, oncology, and advanced manufacturing. By fostering emerging technologies and biological applications, IndieBio plays a crucial role in advancing the next generation of startups that seek to make a positive difference in society.
Bain Capital Life Sciences Investors, LLC is a principal investment firm based in Boston, Massachusetts, focusing on investments in the life sciences sector. The firm specializes in various types of investments, including inflection capital, growth capital, buyouts, and turnaround investments. It targets biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies worldwide. Bain Capital Life Sciences aims to support companies that drive medical innovation and address unmet medical needs, providing not only capital but also strategic assistance to enhance their growth and value during critical phases. The firm's unique expertise in the life sciences landscape allows it to effectively navigate complex investment opportunities and contribute to advancements in healthcare.
Logos Capital is a biotechnology-focused investment firm based in San Francisco, California, founded in 2019. The firm specializes in identifying transformative therapies within the healthcare sector by leveraging in-house data analytics alongside scientific and clinical expertise. Logos Capital integrates knowledge from medical, scientific, and statistical fields to enhance its investment diligence, aiming to uncover compelling opportunities in the biotechnology space. The firm employs a fundamental and sector-oriented approach to equity investment, utilizing statistical modeling of clinical trials to bolster confidence in its investment positions. Through this rigorous methodology, Logos Capital seeks to deliver uncorrelated market returns while advancing innovative healthcare solutions.
Venrock is a venture capital investment firm established in 1969, with its headquarters in Palo Alto, California, and additional offices in New York. The firm specializes in investing in both technology and healthcare sectors, targeting companies within the United States. Venrock employs a rigorous approach that combines venture expertise and data analysis to support the growth of its portfolio companies. Its investment scope includes a diverse range of industries such as biotechnology, consumer products, cybersecurity, defense and aerospace, financial technology, software-as-a-service, and artificial intelligence. By focusing on both publicly-held and privately-held companies, Venrock aims to foster innovation and drive success in the sectors it invests in.
Casdin Capital is a New York-based investment firm established in 2012, specializing in fundamental research within the life sciences and healthcare sectors. The firm focuses on a range of investments, from early-stage to late-stage private opportunities, and is particularly interested in areas such as oncology, digital health, and agtech. As a Registered Investment Adviser, Casdin Capital employs a long-short equity strategy to manage its portfolio. Founded by Eli Casdin, the firm has built a reputation for its analytical approach to investing in innovative healthcare solutions, aiming to capitalize on advancements in the industry. As of October 2020, Casdin Capital managed approximately $2.2 billion in assets.
Foresite Capital is a healthcare and life sciences investment firm founded in 2011 and based in Larkspur, California, with additional offices in San Francisco and New York. The firm adopts a data-driven and scientific approach to identify and invest in startups that leverage biology and big data to enhance healthcare outcomes. Foresite Capital focuses on multiple stages of investment in sectors such as healthcare technology, therapeutics, and life sciences. The firm collaborates closely with its portfolio companies, offering not only capital but also access to a multidisciplinary team of experts, including scientists, engineers, analysts, and clinicians. This collaborative approach aims to address significant unmet clinical needs by supporting innovative healthcare solutions across various stages of development. Foresite Capital manages $2 billion in assets and emphasizes investments in companies utilizing data science and machine intelligence to advance healthcare.
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Takeda Pharmaceutical Company Limited is a global biopharmaceutical leader that focuses on researching, developing, manufacturing, and marketing innovative medicines. The company specializes in a range of therapeutic areas, including oncology, gastroenterology, neuroscience, and rare diseases. With its commitment to improving patient outcomes, Takeda is dedicated to delivering advanced pharmaceuticals and therapeutics, as well as vaccines. Founded in 1781 and headquartered in Japan, Takeda operates worldwide, with significant research and development facilities in locations such as Cambridge, Massachusetts, and San Diego, California. The company also engages in strategic investments through its venture capital arm, which supports early-stage companies and technologies that align with its therapeutic focus, fostering collaborations that leverage its extensive R&D capabilities. Takeda's mission is to enhance the quality of life for patients globally through continuous innovation and excellence in healthcare.
Nextech Invest is a venture capital and private equity firm based in Zurich, Switzerland, established in 1998. The firm focuses on early to late-stage investments in the life sciences, biotechnology, and healthcare sectors, with a particular emphasis on oncology companies developing cancer drugs and diagnostics. Nextech Invest looks for investment opportunities that demonstrate efficacy in preclinical animal models or fulfill prototype requirements for devices. Additionally, the firm is interested in interdisciplinary projects that encompass therapies, diagnostics, medical technologies, and services. It targets investments ranging from CHF 1 million to CHF 5 million per financing round, primarily in companies located in Africa, the Middle East, Asia, North America, and Europe, including Switzerland and Germany. Nextech Invest also considers co-investments in other European regions and typically aims to secure a Board position within its portfolio companies. The firm seeks to exit investments within a three-year timeframe, often through trade sales.
The Michael J. Fox Foundation is a trust fund and a nonprofit research firm. It focuses on finding a cure for Parkinson disease and improved therapies for those living with the condition. The firm operates through a funded and targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors, and volunteers. The Michael J. Fox Foundation was founded by Deborah Brooks in 2000 and is headquartered in New York.
Atlas Venture is an early-stage venture capital firm based in Cambridge, Massachusetts, founded in 1980. The firm specializes in creating and investing in biotech startup companies, primarily in the life sciences sector, and emphasizes a seed-led venture creation strategy. Atlas Venture focuses on identifying and nurturing promising entrepreneurs to build scalable businesses that can deliver significant value. The firm has a history of successful investments, with a portfolio that includes over 350 companies across various countries, resulting in numerous acquisitions and public offerings. Atlas Venture typically invests between $500,000 and $5 million in its early-stage ventures, and its investment team consists of experienced operating executives and venture capitalists. The firm has established separate teams dedicated to life sciences and technology, with the life sciences group retaining the Atlas name.
Accelerate a diverse portfolio of at least 20 high-quality antibacterial products towards clinical development leveraging $250 million in BARDA funds with matching funds from the Wellcome Trust and the AMR Centre.
MPM Capital is a healthcare investment firm that focuses on the biotechnology, healthcare, and life sciences sectors. Established in 1996 and headquartered in Boston, Massachusetts, with additional offices in California and Kansas, the firm specializes in investing in companies that develop therapeutic technologies, particularly in oncology and medical technology. MPM Capital targets a range of investment stages, from seed and early ventures to late-stage biopharmaceutical and diagnostics companies with clinical proof-of-concept. The firm typically invests between $5 million and $50 million and seeks to be a lead investor, often taking interim operating roles within its portfolio companies. Its global investment strategy emphasizes opportunities in the United States, Europe, and Asia, particularly India, with a commitment to translating scientific innovations into clinical outcomes that can significantly impact patient lives.
EASME is a European Union executive agency that supports small and medium-sized enterprises and promotes innovation in Europe. It manages projects in the areas of small and medium-sized enterprises, as well as the environment, energy, and maritime sectors, funded by COSME, LIFE, and EMFF. EASME organizes the European Sustainable Energy Week and serves industries such as environmental management, energy production, and maritime activities.